Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 611

1.

Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis.

Jairath V, Zou GY, Parker CE, MacDonald JK, AlAmeel T, Al Beshir M, Almadi MA, Al-Taweel T, Atkinson NS, Biswas S, Chapman T, Dulai PS, Glaire MA, Hoekman DR, Koutsoumpas A, Minas E, Mosli MH, Samaan M, Khanna R, Travis S, D'Haens G, Sandborn WJ, Feagan BG.

Cochrane Database Syst Rev. 2017 Sep 8;9:CD011572. doi: 10.1002/14651858.CD011572.pub2. [Epub ahead of print] Review.

PMID:
28886205
2.

Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set.

Ma C, Panaccione R, Fedorak RN, Parker CE, Nguyen TM, Khanna R, Siegel CA, Peyrin-Biroulet L, D'Haens G, Sandborn WJ, Feagan BG, Jairath V.

Clin Gastroenterol Hepatol. 2017 Aug 24. pii: S1542-3565(17)30991-6. doi: 10.1016/j.cgh.2017.08.025. [Epub ahead of print] Review.

PMID:
28843356
3.

Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease.

Deepak P, Sandborn WJ.

Gastroenterol Clin North Am. 2017 Sep;46(3):603-626. doi: 10.1016/j.gtc.2017.05.013. Review.

PMID:
28838418
4.

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.

Sandborn WJ, Su C, Panes J.

N Engl J Med. 2017 Aug 3;377(5):496-7. doi: 10.1056/NEJMc1707500. No abstract available.

5.

Histologic scoring indices for evaluation of disease activity in Crohn's disease.

Novak G, Parker CE, Pai RK, MacDonald JK, Feagan BG, Sandborn WJ, D'Haens G, Jairath V, Khanna R.

Cochrane Database Syst Rev. 2017 Jul 21;7:CD012351. doi: 10.1002/14651858.CD012351.pub2. Review.

PMID:
28731502
6.

The development of a magnetic resonance imaging index for fistulising Crohn's disease.

Samaan MA, Puylaert CAJ, Levesque BG, Zou GY, Stitt L, Taylor SA, Shackelton LM, Vandervoort MK, Khanna R, Santillan C, Rimola J, Hindryckx P, Nio CY, Sandborn WJ, D'Haens G, Feagan BG, Jairath V, Stoker J.

Aliment Pharmacol Ther. 2017 Sep;46(5):516-528. doi: 10.1111/apt.14190. Epub 2017 Jun 27.

PMID:
28653753
7.

Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review.

Fumery M, Singh S, Dulai PS, Gower-Rousseau C, Peyrin-Biroulet L, Sandborn WJ.

Clin Gastroenterol Hepatol. 2017 Jun 16. pii: S1542-3565(17)30722-X. doi: 10.1016/j.cgh.2017.06.016. [Epub ahead of print]

PMID:
28625817
8.

Development of a core outcome set for clinical trials in inflammatory bowel disease: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey.

Ma C, Panaccione R, Fedorak RN, Parker CE, Khanna R, Levesque BG, Sandborn WJ, Feagan BG, Jairath V.

BMJ Open. 2017 Jun 9;7(6):e016146. doi: 10.1136/bmjopen-2017-016146.

9.

Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis.

D'Haens GR, Sandborn WJ, Zou G, Stitt LW, Rutgeerts PJ, Gilgen D, Jairath V, Hindryckx P, Shackelton LM, Vandervoort MK, Parker CE, Muller C, Pai RK, Levchenko O, Marakhouski Y, Horynski M, Mikhailova E, Kharchenko N, Pimanov S, Feagan BG.

Aliment Pharmacol Ther. 2017 Aug;46(3):292-302. doi: 10.1111/apt.14164. Epub 2017 Jun 1.

PMID:
28568974
10.

Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial.

Vermeire S, Sandborn WJ, Danese S, Hébuterne X, Salzberg BA, Klopocka M, Tarabar D, Vanasek T, Greguš M, Hellstern PA, Kim JS, Sparrow MP, Gorelick KJ, Hinz M, Ahmad A, Pradhan V, Hassan-Zahraee M, Clare R, Cataldi F, Reinisch W.

Lancet. 2017 Jul 8;390(10090):135-144. doi: 10.1016/S0140-6736(17)30930-3. Epub 2017 May 17.

PMID:
28527704
11.

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.

Sandborn WJ, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, Friedman G, Lawendy N, Yu D, Woodworth D, Mukherjee A, Zhang H, Healey P, Panés J; OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators.

N Engl J Med. 2017 May 4;376(18):1723-1736. doi: 10.1056/NEJMoa1606910.

PMID:
28467869
12.

Corrigendum: Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease.

Khanna R, Zou G, Stitt L, Feagan BG, Sandborn WJ, Rutgeerts P, McDonald JWD, Dubcenco E, Fogel R, Panaccione R, Jairath V, Nelson S, Shackelton LM, Huang B, Zhou Q, Robinson AM, Levesque BG, D'Haens G.

Am J Gastroenterol. 2017 Jun;112(6):975. doi: 10.1038/ajg.2017.120. Epub 2017 Apr 18. No abstract available.

PMID:
28417993
13.

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.

Feagan BG, Sandborn WJ, D'Haens G, Panés J, Kaser A, Ferrante M, Louis E, Franchimont D, Dewit O, Seidler U, Kim KJ, Neurath MF, Schreiber S, Scholl P, Pamulapati C, Lalovic B, Visvanathan S, Padula SJ, Herichova I, Soaita A, Hall DB, Böcher WO.

Lancet. 2017 Apr 29;389(10080):1699-1709. doi: 10.1016/S0140-6736(17)30570-6. Epub 2017 Apr 12.

PMID:
28411872
14.

Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's Disease.

Sandborn WJ, Wolf DC, Kosutic G, Parker G, Schreiber S, Lee SD, Abraham B, Afzali A, Arsenescu RI, Gutierrez A, Spearman M, Coarse J, Feagan BG.

Inflamm Bowel Dis. 2017 Jul;23(7):1047-1056. doi: 10.1097/MIB.0000000000001100.

PMID:
28410341
15.

Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn's Disease.

Vande Casteele N, Mould DR, Coarse J, Hasan I, Gils A, Feagan B, Sandborn WJ.

Clin Pharmacokinet. 2017 Mar 28. doi: 10.1007/s40262-017-0535-3. [Epub ahead of print]

PMID:
28353055
16.

Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial.

Rubin DT, Cohen RD, Sandborn WJ, Lichtenstein GR, Axler J, Riddell RH, Zhu C, Barrett AC, Bortey E, Forbes WP.

J Crohns Colitis. 2017 Jul 1;11(7):785-791. doi: 10.1093/ecco-jcc/jjx032.

PMID:
28333362
17.

Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.

Rosario M, French JL, Dirks NL, Sankoh S, Parikh A, Yang H, Danese S, Colombel JF, Smyth M, Sandborn WJ, Feagan BG, Reinisch W, Sands BE, Sans M, Fox I.

J Crohns Colitis. 2017 Aug 1;11(8):921-929. doi: 10.1093/ecco-jcc/jjx021.

PMID:
28333288
18.

Eldelumab [anti-interferon-γ-inducible protein-10 antibody] Induction Therapy for Active Crohn's Disease: a Randomised, Double-blind, Placebo-controlled Phase IIa Study.

Sandborn WJ, Rutgeerts P, Colombel JF, Ghosh S, Petryka R, Sands BE, Mitra P, Luo A.

J Crohns Colitis. 2017 Jul 1;11(7):811-819. doi: 10.1093/ecco-jcc/jjx005.

PMID:
28333187
19.

Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis.

Allen PB, Olivera P, Emery P, Moulin D, Jouzeau JY, Netter P, Danese S, Feagan B, Sandborn WJ, Peyrin-Biroulet L.

Aliment Pharmacol Ther. 2017 Apr;45(8):1058-1072. doi: 10.1111/apt.13995. Epub 2017 Mar 1. Review.

PMID:
28247573
20.

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials.

Panés J, Sandborn WJ, Schreiber S, Sands BE, Vermeire S, D'Haens G, Panaccione R, Higgins PDR, Colombel JF, Feagan BG, Chan G, Moscariello M, Wang W, Niezychowski W, Marren A, Healey P, Maller E.

Gut. 2017 Jun;66(6):1049-1059. doi: 10.1136/gutjnl-2016-312735. Epub 2017 Feb 16.

Supplemental Content

Loading ...
Support Center